CORDIS
EU research results

CORDIS

English EN
Widening EU-CELAC policy and research cooperation in Personalised Medicine

Widening EU-CELAC policy and research cooperation in Personalised Medicine

Objective

In order to strengthen the global efforts on Personalized Medicine (PerMed) and the cooperation of the EU-CELAC countries to them, a unique Bi-regional consortium of governmental and funding organisations is shaped with the support of leading stakeholders as associated partners. This project has the ambition to engage CELAC countries in the International Consortium on Personalized Medicine (ICPerMed) and in the ERANet ERAPerMed with the aim at advancing in the implementation of the Action Plan of ICPerMed based in the Strategic Research and Innovation Agenda, drafted by PerMed2020.

Research on PerMed is a top priority for the EU as a strategy aimed at delivering personalised health and care solutions to benefit citizens. Results of R&I actions will generate and translate knowledge on disease aetiology and technological innovation into personalised health and care solutions. Areas of application include chronic, rare and communicable diseases. Research under this priority will also attempt to develop an outstanding economic impact due to the potential of PerMed to transform health systems.

The collaboration of diverse actors from different world regions, disciplines and health-care systems are needed to implement in a holistic way new feasible and cost-effective PerMed approaches. Involvement in ICPerMed of RFOs and policy-making bodies from EU and from other regions, is the best way to push forward the impact of new findings and knowledge in the area.

This CSA will be the vehicle for: i) Mapping existing programmes, capacities and expertise and gaps in CELAC countries; ii) Facilitating the incorporation of CELAC countries in ICPerMed and in the ERAPerMed; iii) Fostering the participation of CELAC countries in research mobility and transnational projects on PerMed, and a platform for EU‐CELAC collaboration on clinical trials PerMed focused; iv) Cross-border learning from R&I and ELSA for implementing innovations between research capacities based in EU and CELAC.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUTO DE SALUD CARLOS III

Address

Monforte De Lemos 5
28029 Madrid

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 392 093,75

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV

Germany

EU Contribution

€ 463 250

FUNDACAO OSWALDO CRUZ

Brazil

MINISTERO DELLA SALUTE

Italy

EU Contribution

€ 318 500

COMISION NACIONAL DE INVESTIGACION CIENTIFICA Y TECNOLOGICA

Chile

EU Contribution

€ 98 750

SOCIEDAD PARA EL FOMENTO DE LA INNOVACION TECNOLOGICA S.L. - INNOVATEC

Spain

EU Contribution

€ 235 525

ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK

France

EU Contribution

€ 291 250

AGENCIA NACIONAL DE INVESTIGACION E INNOVACION

Uruguay

EU Contribution

€ 54 375

INSTITUTO COMMEMORATIVO GORGAS DE ESTUDIOS DE LA SALUD

Panama

EU Contribution

€ 59 375

MINISTRY OF HEALTH

Israel

EU Contribution

€ 48 125

SECRETARIA DE GOBIERNO DE CIENCIA, TECNOLOGÍA E INNOVACIÓN PRODUCTIVA

Argentina

EU Contribution

€ 38 750

Project information

Grant agreement ID: 825173

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2021

Funded under:

H2020-EU.3.1.6.

  • Overall budget:

    € 2 065 618,75

  • EU contribution

    € 1 999 993,75

Coordinated by:

INSTITUTO DE SALUD CARLOS III

Spain